Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Leerink Partners Downgrades CymaBay Therapeutics to Market Perform, Announces $32.5 Price Target

Author: Benzinga Newsdesk | February 20, 2024 06:05am
Leerink Partners analyst Thomas Smith downgrades CymaBay Therapeutics (NASDAQ:CBAY) from Outperform to Market Perform and announces $32.5 price target.

Posted In: CBAY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist